- Home
- AUPH vs INVA Comparison
AUPH vs INVA Comparison
Compare AUPH & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- INVA
- Stock Information
- Founded
- AUPH 1993
- INVA 1996
- Country
- AUPH Canada
- INVA United States
- Employees
- AUPH N/A
- INVA N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- INVA Health Care
- Exchange
- AUPH Nasdaq
- INVA Nasdaq
- Market Cap
- AUPH 1.1B
- INVA 1.2B
- IPO Year
- AUPH 1999
- INVA 2004
- Fundamental
- Price
- AUPH $8.19
- INVA $21.58
- Analyst Decision
- AUPH Strong Buy
- INVA Buy
- Analyst Count
- AUPH 2
- INVA 1
- Target Price
- AUPH $11.50
- INVA $55.00
- AVG Volume (30 Days)
- AUPH 1.4M
- INVA 815.1K
- Earning Date
- AUPH 07-31-2025
- INVA 07-30-2025
- Dividend Yield
- AUPH N/A
- INVA N/A
- EPS Growth
- AUPH N/A
- INVA N/A
- EPS
- AUPH 0.27
- INVA N/A
- Revenue
- AUPH $247,295,000.00
- INVA $369,844,000.00
- Revenue This Year
- AUPH $12.15
- INVA $3.75
- Revenue Next Year
- AUPH $18.31
- INVA $12.62
- P/E Ratio
- AUPH $30.78
- INVA N/A
- Revenue Growth
- AUPH 29.20
- INVA 18.70
- 52 Week Low
- AUPH $5.15
- INVA $15.56
- 52 Week High
- AUPH $10.67
- INVA $21.60
- Technical
- Relative Strength Index (RSI)
- AUPH 54.75
- INVA 86.95
- Support Level
- AUPH $7.91
- INVA $18.59
- Resistance Level
- AUPH $8.07
- INVA $19.08
- Average True Range (ATR)
- AUPH 0.24
- INVA 0.42
- MACD
- AUPH -0.00
- INVA 0.25
- Stochastic Oscillator
- AUPH 51.85
- INVA 99.35
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.